FR23C1006I1 - GIP AND GLP-1 CO-AGONIST COMPOUNDS - Google Patents

GIP AND GLP-1 CO-AGONIST COMPOUNDS

Info

Publication number
FR23C1006I1
FR23C1006I1 FR23C1006C FR23C1006C FR23C1006I1 FR 23C1006 I1 FR23C1006 I1 FR 23C1006I1 FR 23C1006 C FR23C1006 C FR 23C1006C FR 23C1006 C FR23C1006 C FR 23C1006C FR 23C1006 I1 FR23C1006 I1 FR 23C1006I1
Authority
FR
France
Prior art keywords
gip
glp
agonist compounds
agonist
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1006C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1006(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of FR23C1006I1 publication Critical patent/FR23C1006I1/en
Application granted granted Critical
Publication of FR23C1006I2 publication Critical patent/FR23C1006I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
FR23C1006C 2015-01-09 2023-01-31 CO-AGONIST COMPOUNDS OF GIP AND GLP-1 Active FR23C1006I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101488P 2015-01-09 2015-01-09
PCT/US2016/012124 WO2016111971A1 (en) 2015-01-09 2016-01-05 Gip and glp-1 co-agonist compounds

Publications (2)

Publication Number Publication Date
FR23C1006I1 true FR23C1006I1 (en) 2023-03-24
FR23C1006I2 FR23C1006I2 (en) 2024-01-05

Family

ID=55315708

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1006C Active FR23C1006I2 (en) 2015-01-09 2023-01-31 CO-AGONIST COMPOUNDS OF GIP AND GLP-1

Country Status (45)

Country Link
US (1) US9474780B2 (en)
EP (2) EP3597662A1 (en)
JP (3) JP6219534B2 (en)
KR (4) KR20230023822A (en)
CN (2) CN107207576B (en)
AR (1) AR103242A1 (en)
AU (1) AU2016205435B2 (en)
CA (1) CA2973352C (en)
CL (1) CL2017001760A1 (en)
CO (1) CO2017006737A2 (en)
CR (1) CR20170310A (en)
CY (1) CY1122028T1 (en)
DK (1) DK3242887T3 (en)
DO (1) DOP2017000153A (en)
EA (3) EA035055B1 (en)
EC (1) ECSP17043648A (en)
ES (1) ES2747928T3 (en)
FI (1) FIC20230005I1 (en)
FR (1) FR23C1006I2 (en)
HR (1) HRP20191614T1 (en)
HU (2) HUE045860T2 (en)
IL (3) IL252499B (en)
JO (2) JOP20200119A1 (en)
LT (2) LT3242887T (en)
MA (2) MA50422A (en)
MD (1) MD3242887T2 (en)
ME (1) ME03494B (en)
MX (2) MX2017008927A (en)
MY (1) MY193616A (en)
NL (1) NL301217I2 (en)
NO (1) NO2023005I1 (en)
NZ (1) NZ732000A (en)
PE (1) PE20170954A1 (en)
PH (1) PH12017501252A1 (en)
PL (1) PL3242887T3 (en)
PT (1) PT3242887T (en)
RS (1) RS59146B1 (en)
SG (1) SG11201705603YA (en)
SI (1) SI3242887T1 (en)
SV (1) SV2017005453A (en)
TN (1) TN2017000198A1 (en)
TW (1) TWI582109B (en)
UA (1) UA118239C2 (en)
WO (1) WO2016111971A1 (en)
ZA (1) ZA201703930B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
TWI622596B (en) 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonists
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (en) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co Peptide compound
US11590237B2 (en) 2017-05-18 2023-02-28 Merck Sharp & Dohme Llc Pharmaceutical formulation comprising incretin-insulin conjugates
TWI744579B (en) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 Incretin analogs and uses thereof
TWI767095B (en) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 Incretin analogs and uses thereof
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
PE20210473A1 (en) * 2018-05-04 2021-03-08 Novo Nordisk As DERIVATIVES OF GIP AND USES OF THEM
TWI705820B (en) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1 agonist compositions
TW202332688A (en) * 2018-07-23 2023-08-16 美商美國禮來大藥廠 Gip/glp1 co-agonist compounds
EP3826662A1 (en) * 2018-07-23 2021-06-02 Eli Lilly and Company Method of using a gip/glp1 co-agonist for diabetes
MX2021000794A (en) * 2018-07-23 2021-04-12 Lilly Co Eli Methods of using a gip/glp1 co-agonist for therapy.
JP6564539B1 (en) 2018-09-14 2019-08-21 長瀬産業株式会社 Peptide purification method using sulfonic acid compound
JP2022500483A (en) 2018-09-24 2022-01-04 武田薬品工業株式会社 GIP receptor agonist peptide compound and its use
TWI799680B (en) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 Process for preparing a gip/glp1 dual agonist
AU2020291012A1 (en) 2019-06-12 2021-12-16 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
AR119471A1 (en) 2019-08-01 2021-12-22 Lilly Co Eli GIPR AGONIST COMPOUNDS
WO2021034815A1 (en) 2019-08-19 2021-02-25 Eli Lilly And Company Methods of making incretin analogs
JP2022551282A (en) 2019-10-04 2022-12-08 ハンミ ファーマシューティカル カンパニー リミテッド Compositions Comprising Glucagon and GLP-1 Receptor and GIP Receptor Dual Agonists and Therapeutic Uses Thereof
CN110684082B (en) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 GIP and GLP-1 dual-agonist polypeptide compound, pharmaceutically acceptable salt and application
TWI795698B (en) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 Incretin analogs and uses thereof
IL294955A (en) 2020-01-23 2022-09-01 Lilly Co Eli Gip/glp1 co-agonist compounds
TW202228762A (en) * 2020-01-30 2022-08-01 美商美國禮來大藥廠 Therapeutic uses of tirzepatide
CN111253475B (en) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 GLP-1 agonist polypeptide compound and salt thereof, and synthesis method and application thereof
AU2021229621B2 (en) 2020-03-06 2023-08-31 Sanofi Peptides as selective GIP receptor agonists
CN113493503B (en) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 Incretin analogue and preparation method and application thereof
TW202216746A (en) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 Long acting glp-1/gip dual agonists
EP4185607A1 (en) * 2020-07-22 2023-05-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
IL299707A (en) 2020-07-22 2023-03-01 Novo Nordisk As Glp-1 and gip receptor co-agonists
CN114729060B (en) * 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 Polypeptide conjugates and methods of use
EP4204440A1 (en) 2020-10-17 2023-07-05 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
EP4257597A1 (en) * 2020-12-02 2023-10-11 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Lactam-modified polypeptide compounds
KR20230125093A (en) * 2021-01-20 2023-08-28 바이킹 테라퓨틱스 인코포레이티드 Compositions and methods for the treatment of metabolic and liver diseases
JP2024510090A (en) 2021-02-17 2024-03-06 イーライ リリー アンド カンパニー Tirzepatide treatment method
CN117320740A (en) * 2021-02-17 2023-12-29 伊莱利利公司 GIP/GLP1 dual agonist treatment methods
CN117222661A (en) 2021-03-25 2023-12-12 博瑞生物医药（苏州）股份有限公司 Dual receptor agonists of GIP and GLP-1, pharmaceutical compositions and uses
WO2022235991A1 (en) 2021-05-07 2022-11-10 Eli Lilly And Company Erodible tablet
CN117866050A (en) * 2021-05-28 2024-04-12 广东众生睿创生物科技有限公司 Preparation and application of polypeptide
CA3222051A1 (en) * 2021-06-01 2022-12-08 Nanjing Zhihe Medicine Technology Co., Ltd. Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof
TW202302624A (en) * 2021-06-18 2023-01-16 大陸商廣東眾生睿創生物科技有限公司 Polypeptide compound containing lactamide bridge
WO2023031455A1 (en) 2021-09-06 2023-03-09 Sanofi Sa New peptides as potent and selective gip receptor agonists
WO2023044290A1 (en) * 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023089594A1 (en) 2021-11-22 2023-05-25 Sun Pharmaceutical Industries Limited Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof
TW202330584A (en) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 Prodrugs and uses thereof
WO2023193727A1 (en) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 Pharmaceutical use of polypeptide in preparation of drugs for treating and/or preventing diabetes and obesity and related diseases thereof
WO2024006662A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Tirzepatide compositions and use
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024012472A1 (en) * 2022-07-13 2024-01-18 杭州中美华东制药有限公司 Glp-1/gip dual agonist, and preparation method therefor and use thereof
WO2024020388A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
WO2024059674A1 (en) * 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds
WO2024061310A1 (en) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis
CN116832141B (en) * 2023-06-06 2024-02-09 诺博泰科(成都)生物科技有限公司 GLP-1, GIP and GCG receptor tri-agonist polypeptide compound for treating diabetes
CN116693652B (en) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 GLP-1/GIP receptor dual agonist derivative and preparation method and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
ES2490243T3 (en) 2005-02-02 2014-09-03 Novo Nordisk A/S Insulin derivatives
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EA020005B1 (en) * 2008-08-07 2014-07-30 Ипсен Фарма С.А.С. Glucose-dependent insulinotropic polypeptide analogues
EP2340049B1 (en) 2008-09-12 2015-11-11 Novo Nordisk A/S Method of acylating a peptide or protein
CN101367873B (en) * 2008-10-08 2011-05-04 南开大学 Modified glucagon sample peptide-1analogue and modifying matter, and uses thereof
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
AR080592A1 (en) 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
KR101091041B1 (en) * 2010-07-29 2011-12-09 고려대학교 산학협력단 Novel recombinant glucose-dependent insulinotropic polypeptide agonists and use thereof
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
JP2014501762A (en) * 2010-12-22 2014-01-23 マルケイディア バイオテック， インコーポレイテッド Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor active glucagon peptides
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
KR102002783B1 (en) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
JP6058646B2 (en) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス Multi-substituted insulin
IN2014CN02448A (en) * 2011-09-23 2015-06-19 Novo Nordisk As
US20130316941A1 (en) * 2011-12-23 2013-11-28 Boehringer Ingelheim International Gmbh Glucagon analogues
TWI689515B (en) * 2012-05-03 2020-04-01 丹麥商西蘭製藥公司 Gip-glp-1 dual agonist compounds and methods
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
KR102229051B1 (en) * 2013-05-28 2021-03-16 다케다 야쿠힌 고교 가부시키가이샤 Peptide compound

Also Published As

Publication number Publication date
JP6545766B2 (en) 2019-07-17
AU2016205435B2 (en) 2018-03-29
MA41315B1 (en) 2019-11-29
ES2747928T3 (en) 2020-03-12
MA41315A (en) 2017-11-15
MA50422A (en) 2020-08-26
JP2018052933A (en) 2018-04-05
NO2023005I1 (en) 2023-02-02
KR20170092661A (en) 2017-08-11
ME03494B (en) 2020-01-20
TN2017000198A1 (en) 2018-10-19
HUE045860T2 (en) 2020-01-28
KR20190026967A (en) 2019-03-13
CN112608377A (en) 2021-04-06
CA2973352A1 (en) 2016-07-14
CL2017001760A1 (en) 2018-03-16
EA031591B1 (en) 2019-01-31
AU2016205435A1 (en) 2017-06-08
US9474780B2 (en) 2016-10-25
SI3242887T1 (en) 2019-10-30
MX2021005835A (en) 2021-07-15
CR20170310A (en) 2017-08-17
ECSP17043648A (en) 2017-11-30
KR102330764B1 (en) 2021-11-25
CN107207576B (en) 2020-11-24
JP2017507124A (en) 2017-03-16
EP3242887A1 (en) 2017-11-15
ZA201703930B (en) 2019-06-26
UA118239C2 (en) 2018-12-10
IL281545A (en) 2021-05-31
RS59146B1 (en) 2019-09-30
EA201791281A1 (en) 2017-11-30
HUS2300006I1 (en) 2023-02-28
JOP20200119A1 (en) 2017-06-16
SG11201705603YA (en) 2017-08-30
NL301217I1 (en) 2023-02-15
LTPA2023504I1 (en) 2023-02-27
PL3242887T3 (en) 2020-02-28
SV2017005453A (en) 2018-08-27
NZ748274A (en) 2022-03-25
KR20230023822A (en) 2023-02-17
EP3597662A1 (en) 2020-01-22
JO3575B1 (en) 2020-07-05
NZ732000A (en) 2018-11-30
JP6754867B2 (en) 2020-09-16
JP2019203000A (en) 2019-11-28
IL276492B (en) 2021-04-29
NL301217I2 (en) 2023-04-04
PT3242887T (en) 2019-10-29
HRP20191614T1 (en) 2019-12-13
AR103242A1 (en) 2017-04-26
LT3242887T (en) 2019-11-11
US20160199438A1 (en) 2016-07-14
TW201636362A (en) 2016-10-16
JP6219534B2 (en) 2017-10-25
FR23C1006I2 (en) 2024-01-05
IL252499A0 (en) 2017-07-31
TWI582109B (en) 2017-05-11
BR112017010596A2 (en) 2018-03-06
CN107207576A (en) 2017-09-26
WO2016111971A1 (en) 2016-07-14
CY1122028T1 (en) 2020-10-14
CA2973352C (en) 2019-03-26
MD3242887T2 (en) 2019-11-30
EA202090392A3 (en) 2020-08-31
EP3242887B1 (en) 2019-08-14
KR101957620B1 (en) 2019-03-13
PH12017501252A1 (en) 2017-10-30
IL276492A (en) 2020-09-30
FIC20230005I1 (en) 2023-02-02
EA202090392A2 (en) 2020-05-31
MX2017008927A (en) 2017-10-11
KR20210145311A (en) 2021-12-01
MY193616A (en) 2022-10-20
EA201892057A1 (en) 2019-02-28
CN112608377B (en) 2024-02-13
CO2017006737A2 (en) 2017-09-29
IL252499B (en) 2020-08-31
EA035055B1 (en) 2020-04-22
DOP2017000153A (en) 2017-07-15
DK3242887T3 (en) 2019-09-02
PE20170954A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
FR23C1006I1 (en) GIP AND GLP-1 CO-AGONIST COMPOUNDS
IL285231A (en) Glucagon and glp-1 co-agonist compounds
MA49549A (en) AUTO-INJECTOR
DK3212218T3 (en) GIP agonist compounds and methods
MA45709A (en) SUBSTITUTED DIAZAHETERBICYCLIC COMPOUNDS AND THEIR USE
DK3163339T3 (en) POLARIZATION-CONSERVING MULTICERN FIBER
DK3334856T3 (en) PHOSPHONED PBI FIBER
ES1103780Y (en) Sleeve fixer
FI11230U1 (en) Enclosures
UA31739S (en) LOGOTYPE
UA30170S (en) LOGOTYPE
UA29506S (en) LOGOTYPE
UA29160S (en) LOGOTYPE
UA29308S (en) LOGOTYPE
UA29307S (en) LOGOTYPE
BR302014001881S1 (en) Pool Applied Configuration
BR302014000760S1 (en) POOL CONFIGURATION
BR302014000759S1 (en) POOL CONFIGURATION
BR302014000757S1 (en) POOL CONFIGURATION
BR302014000758S1 (en) POOL CONFIGURATION
TH1601006713A (en) The core absorbs
TH167385B (en) Absorbent core